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Background: The Human Papillomavirus (HPV) has different strategies for persist in the cells. This characteristic 
has led us to consider the presence of the virus in tissues of the oral cavity that had no clinical signs of infection. 
The aim of this study was to detect the presence of DNA-HPV at multiple sites of the oral cavity.
Material and Methods: A case-control study was designed: Oral Squamous Carcinoma Group (OSCG), healthy 
n=72 and Control Group (CG), n=72, healthy volunteers paired by sex and age with OSCG. Four samples were 
taken from OSCG: saliva, biopsy, brush scraping of lesion and contralateral healthy side. In CG a saliva sample 
and a scratch of the posterior border of tongue were collected. HPV was detected by PCR using Bioneer Accuprep 
genomic DNA Extraction kit, and consensus primers MY09 and MY11. Chi square test was applied.
Results: 432 samples were obtained from 144 individuals. DNA-HPV was detected in 30 (42%) of OSCG subjects 
and 3 (4%) of CG. Two or more positive samples were obtained in 67% of the OSCG, 67% in saliva and 60% in 
biopsy; in CG 100% of the individuals were positive in the two samples.
Conclusions: HPV is frequently present in oral cavity as a multifocal infection, even without the presence of clini-
cal lesions.
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Introduction
The first cells to become in contact with the human pap-
illomavirus (HPV) in the oral cavity, as in the genital 
mucosa, are undifferentiated cells of the basal layer of 
the epithelium. This contact implies the previous exis-
tence of ulceration or micro-wounds on the epithelial 
surface that allows its entry (1-3). Viral DNA and RNA 
transcriptions occurs in the basal layer, whereas viral 
replication occurs in the most differentiated layers of 
the epithelium (4,5). This association between viral rep-
lication and progressive differentiation would involve a 
strategy to persist in a host with high cell proliferation 
(6). In addition, the virus can evade the innate immune 
system, delaying the adaptive immune response. Infect-
ed cells are pushed out towards the epithelial surface, 
away from the circulating immune system, and there-
fore no viremia occurs. In conclusion, the lack of cell 
death and inflammatory response makes HPV a “suc-
cessful microorganism” for infection (7). This charac-
teristic of the virus has led us to consider the possible 
presence of HPV in saliva or samples of other tissues 
of the oral cavity that had no clinical signs of infection 
and to think whether the presence of the virus could 
occur silently or latently in multiple sites of the oral cav-
ity simultaneously. We also consider, as other authors, 
that areas of constant rubbing in the mouth, such as the 
lateral border of the tongue, could be the first site of 
exposure to the virus (8).
We do not find in the current literature at our disposal, 
studies on the presence of simultaneous HPV infection 
in different tissues of the oral mucosa. Nevertheless, 
some authors reported the presence of HPV in different 
sites of the anogenital tract without clinical symptoms 
of infection. These studies report cases of simultaneous 
infection of the oral and genital mucosa (9-11). Stud-
ies on the prevalence of oral HPV infection in healthy 
individuals have revealed a high variability in differ-
ent populations, with values ranging between 0.2% and 
20.7% (12). Tables shows prevalence of oral HPV infec-
tion in healthy individuals of different populations.
The objective of this work was to detect the presence of 
DNA-HPV in multiple sites of the oral cavity.
Material and Methods
A case-control study was designed and conducted be-
tween 2010 to 2017, which was approved by the In-
stitutional Committee of Ethics in Health Research 
from the School of Dentistry, Universidad Nacional de 
Córdoba (CIEISN°6/2010). All the subjects signed an 
informed consent.
- Study groups
Two groups were considered:
a- Oral Squamous Carcinoma Group (OSCG): 72 pa-
tients with diagnosis of oral squamous cells carcinoma; 
b- Control Group (CG):72 clinically healthy at the oral 
cavity, which means, with any oral clinical lesions at the 
time of this study, paired by sex and age (+/- 5) with the 
OSCG. This group was relieved from a population study 
titled “Survey of oral health parameters in the adult 
population from Córdoba city 2014–15” done in the city 
of Córdoba, Argentina. A multistage cluster sampling 
was conducted, with random selection of census tracts, 
probability proportional to size, blocks, households, and 
persons; the same number of individuals per tract was 
selected. The included subjects were asked to attend a 
health center in the area. Pregnant women and subjects 
under age 18 were excluded. The results were informed 
by phone or via mail to patients and healthy controls and 
they were also clinically controlled.
- Data collection
Clinical history of all patients was recorded, including 
personal data, personal and hereditary records, risk fac-
tors and oral health state. Subjects were inspected by 
personnel trained for clinical diagnosis. OSCG were 
subjected to biopsy to obtain diagnostic certainty. The 
data on tobacco consumption was made according the 
number of pack year smoked; a subject that smoked fif-
teen or more pack years in twenty years was considered 
a smoker (13). One alcohol unit a day (one drink) was 
considered as regular alcohol consumption (14).
- Sample collection
Four samples per patient were obtained from the OSCG: 
1-unstimulated whole saliva collected in sterile tube; 
2-cytobrush of lesion; specimens were placed in ster-
ile tube containing 2 ml phosphate buffer solution with 
antibiotic and antifungal agents; 3-cytobrush of healthy 
contralateral mucosa to the lesion site, as in 2; and 4- 
biopsy of lesion; samples were placed in sterile tube 
in fresh conditions. All samples were preserved at 4°C 
until DNA extraction. The CG group was subjected to 
saliva sampling and cytological analysis of the posterior 
border of the tongue, using the same technique as in 
OSCG. In this group, we chose this area for being one of 
the most exposed to micro-wounds that would facilitate 
the entry of the virus.
- Sample processing
DNA-HPV was detected via PCR using Bioneer Accu-
Prep genomic DNA Extraction kit, and consensus prim-
ers MY09 and MY11. These primers amplified a frag-
ment of approximately 450 base pairs corresponding to 
the highly conserved L1 region of the virus genome. 
The method involved a 50 μl reaction mix containing 10 
μl DNA, 1.5 mM MgCl2, 200 μM of each dNTP (dATP, 
dCTP, dGTP and dTTP), 10 pmoles of each oligonucle-
otide primer and 1 U Taq DNA polymerase (Promega 
Corporation, Madison, USA). The temperature profile 
used for amplification constituted an initial denatur-
ation at 94°C for 3 min followed by 35 cycles with dena-
turation at 94°C for 1 min, annealing at 55°C for 1 min 
and extension at 72°C for 1 min which was extended 
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for 5 min in the final cycle. Typing was performed by 
means of the analysis of the amplified product using 
the enzyme restriction fragment length polymorphism 
(RFLP) with the following restriction enzymes: Bam 
H1, Dde I, Hae III, Hinf I, Pst I, Rsa I, and Sau3 AI. A 
mixed of PCR product and buffer was prepared to each 
enzime separately for subsequent addition of individ-
ual restriction enzymes. The mix included 6.5 µl PCR 
product, 2 µl buffer, 1.5 µl restriction enzyme, followed 
by incubation 40ºC for 60 min. The result was a charac-
teristic banding pattern visualized with UV light (15). 
Subjects with at least one positive sample were consid-
ered HPV+, this means an HPV infection of the sample. 
- Statistical analysis
Data were expressed as relative frequencies; data asso-
ciation was analyzed using the chi square test, and OR 
was used to reveal the intensity of the association.
Results
Two study groups were formed with 144 subjects, corre-
sponding 72 to each group. The total of samples obtained 
from both was 432. Table 1 describes the general charac-
teristics of both groups or of each of the two groups.
- Sample analysis: DNA-HPV was detected in 30 (42%) 
patients of OSCG and 3 (4%) in subjects of CG. The 
analysis and comparison of the results of OSCG with 
controls showed a highly significant difference, with an 
OR of 16.43 (CI: 5.10-52.94), p<0.0001 (Table 2).
- DNA-HPV at multiple sites: 67% of the HPV+ patients 
of OSCG had two or more positive samples. In the case 
of CG, 100% of the cases were positive in both samples 
Table 3 describes the distribution of positive samples in 
both groups. Four positive samples prevail in OSCG, 
where the most frequent positive sample was in saliva 
(67%), followed by biopsy (60%).
Table 1: Prevalence of oral HPV infection in healthy individuals.
Year         Country Sample Samplesize n Age
Prevalence
n (%) Genotypes Author
1994-96 Grace cytobrush 169 14-85 19 (9.5) 6/16/11 Lambropoulos et al.
2000-02 Miyako Island, Japan cytobrush 668 3-85 4(0.6) 16/53/71/12 Kurose et al.
2006 SJR Preto, Brazil cytobrush 50 16-52 7(14) 18/18/52/61 Do Sacramento et al.
2000-06   Ohio, USA                     oral rinse 542          25-87          22(4.06) 16/51/56/59/6/1 D Souza et al.
2007         Sardinia, Italy saliva 164 4-77 30(18.3) 1/42/16/31 Montaldo et al.
2006-7 Brazil cytobrush 100  20-31 0 NS Esquenazi et al.
2009-10 Ohio, USA oral rinse 5579          14-69 385(6.9) 16/62/55/84/72 Guillison et al.
2009-11 China oral swabs 5351        25-65 36 (0.67) 16/45/58 Hang et al.
2012       Modena, Italy cytobrush.  81 49-77 1(1.2) 16 Migaldi et al.
2013 Australia oral rinse 307 18-35        7(2.3) 18/16/67/69/90 Antonsson et al.
2014-15   Treviso, Italy oral rinse 500 19-35 20(4.0) 16/56/6/11/81/5  2/30/53/90 Lupato et al.
2014-15 Córdoba, Argentina cytobrush 401 18-87 13(3.3) 11/84/6/81 Criscuolo et al.
MI Criscuolo, et al. Translational Research in Oral Oncology 3: (1–8) 2018.
Characteristics TOTAL OSCG CG OR P
 n  (%)       n  (%) n  (%)   
Gender      
F 66(46) 33(46) 33(46)
------ ------
M 78(54) 39(54) 39(54)
Mean age 62 64,5 63 ------ ------
Tabaco      
Yes 61(42) 37(51) 24 33) 2(1,08-4,12) p<0,03
No 83(58) 35(49) 48(67)
Alcohol      
Yes 71(49) 35(49) 36(50)
0,92(0,48-1,76) p<0,87
No  73(51) 37(51) 36(50)
HPV    
Yes 33(23) 30(42) 3 (4) 16.43(5.10-52.94) p<0.0001
No 111(7) 42(58) 69 (96)
Total                144 72 72
OSCG: Oral Squamous Cancer Group, CG: Control Group, OR: Odd Ratio
Table 2: General characteristics of the study groups.
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When positive patients in two or more sites in the OSCG 
were analyzed and was related with the tumors site, we 
observed that the 65% were located at the border of the 
tongue and oropharynx.
- Genotypes: The genotypes were 16/ 6/ 11/ 31/ 33/ 45/ 
52/ 53/ 69, with 16/ 6/ 11 being the most frequent. In 
nine samples of the OSCG it was not possible to identify 
the genotype. In the OSCG, 12 patients (40%) had high-
risk genotypes: 16/ 52/ 45/ 31/ 69 and 33, with 50% of 
these being HPV 16. Of the remaining positive types, 
9 patients (30%) were of low risk (6/11); one of these 
patients had combination of genotypes 6 and 11, and of 
the remaining nine patients (30%) were not genotyped. 
In CG all genotypes were of low risk (11/84).
Discussion
The results of the present work show the prevalence of 
positive samples in more than one site of the oral cavity 
in DNA-HPV positive subjects of the groups studied. 
We also observed that in healthy mucosa the virus was 
present despite the lack of clinical signs of infection. 
In fact, 100% of controls and 43% of patients with oral 
cancer were positive in healthy mucosa.
Some authors assume that HPV could present as a mul-
tifocal infection in different mucous membranes (16-
19). Our results effectively confirm that oral DNA-HPV 
appears as a simultaneous infection in different sites of 
the mouth.
In spite of not finding in the current literature, stud-
ies like ours, we found some authors who had studied 
the virus in different conditions such as HIV positive 
patients or groups at risk for diseases such as sexu-
ally transmitted diseases. Authors like Ciccarese et al. 
studied the HPV in a risk group of sexually transmit-
ted diseases, and evaluated the presence of the virus at 
different sites with no clinical signs of infection. They 
took samples from the oral, genital and anal mucosa. 
The highest values were recorded in genital samples, 
and 37% of HPV positive values were obtained in the 
oral cavity. This result is similar to the values found in 
the samples taken in the present work in the carcinoma 
group. It should be noted that although they obtained 
similar percentages in both sexes, 51% of HPV positive 
males in the oral cavity had simultaneous genital infec-
tion, resulting in a significant association, with an OR of 
3.63 (CI 1.37-9.58) (9). On the other hand, Ucciferri et al. 
studied HPV in 90 males, 45 HIV+ and 45 HIV-, in oral, 
anal, urethral mucosa and coronal sulcus samples. The 
results showed that 59% of the subjects had infection at 
multiple sites, 34% at two sites and 22% at three sites. 
It is important to note that in oral mucosa HPV positive 
patients did not exhibit different values between HIV 
positive and negative subjects (10). In a similar study 
(20) where studied HPV at oral, genital and anal mucosa 
in HIV positive and negative males, observed that the 
virus was detected in the three samples simultaneously 
in 14% and 10% respectively. In Peru, Blas et al. stud-
ied the detection of HPV at multiple sites in men who 
had sex with men, HIV positives and negatives; they 
obtained samples from oral, anal, and genital mucosa 
and blood. Although the report does not provide the per-
centage of HPV positive cases at several sites simulta-
neously, at the oral cavity level the values were similar 
in both groups, with 8.5% in HIV positive subjects and 
9.9% in HIV negative subjects. The highest HPV per-
centage recorded was in anal mucosa of HIV positive 
patients; high risk genotypes were the most prevalent 
(86%) in this group and at this site, and HPV 16 was the 
most frequent. In oral mucosa, HIV positive cases had 
a higher percentage of high-risk genotypes than HIV 
negative cases (21,22). In our study, the most frequent 
genotypes were 16/6/11 and the oral cancer group was 
the one with highest percentage of high-risk HPV and, 
as in the previously mentioned study, HPV 16 was the 
most frequent genotype. In the current clinical cases, 
we do not find HPV 18, a high-risk genotype that is fre-
quently found in the literature (23). Table 4 compares 
the prevalence of HPV in OSCC patients of different 
studies and the highest frequency of HR-HPV in these 
groups (24).










One site 3(30) 2(20) 3(20) 2(20) 10 (15)
2 sites 6(33) 7(39) 3(17) 2(11) 18 (27)
3 sites 5(33) 3(20) 4(27) 3(20) 15 (22)
4 sites 6(25) 6(25) 6(25) 6(25) 24 (36)
CG 
One site - - - - -
2 sites a 3(50) - - 3(50) 6 (100)
a In CG samples were taken only from saliva and posterior border of the tongue
Table 3: Distribution of HPV in different sites.
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We believe important that these results of virus detec-
tion and the expression of predominant genotypes in 
both sexes are useful to support educational campaigns 
and the need to apply HPV preventive vaccines. Al-
though the World Health Organization recommends the 
inclusion of males in HPV vaccination strategies, only 
in some countries like Argentina these are applied pre-
ventively since 2017, in both sexes (25).
Regarding our findings of a high positive DNA-HPV 
percentage in saliva, similar to that in tissue subjected 
to biopsy, several authors have discussed the utility of 
detecting the virus in this fluid. Zhao et al. analyzed 
HPV 16 in saliva of patients with head and neck car-
cinoma and compared it with a healthy control group; 
they found significant differences between groups (26). 
In our results, saliva samples of all the HPV positive 
cases of the healthy volunteer group were positive, de-
spite the lack of lesions suggestive of DNA-HPV infec-
tion.
Conclusions
Oral cavity HPV often occurs as a multifocal infection, 
even without the presence of clinical lesions. The cur-
rent vaccination scheme in Argentina prevents against 
the genotypes circulating in our medium. Future studies 
are necessary to assess the clinical and epidemiological 
implications of the virus presence in saliva.
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